Cardiometabolic & kidneyRandomised controlled trial
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
- event-driven
- superiority
- Mean exposure 34.2±13.7 months
Authors' conclusion
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months.
Study context
- Population
- Patients ≥45 years with preexisting CVD and BMI ≥27, without history of diabetes
- Participants
- 17,604 patients
- Comparison
- Semaglutide 2.4 mg weekly vs placebo
- Semaglutiden = 8,803
- Placebon = 8,801reference
- Primary endpoint
- Composite of:
- CV death
- Nonfatal MI
- Nonfatal stroke (time-to-first-event)
- Follow-up
- Mean 39.8±9.4 months
Primary result
As reported in the abstract
Hazard ratio
0.80
95% CI 0.72–0.90
P < 0.001
Events by treatment group
Semaglutide vs Placebo
HR 0.80 (95% CI 0.72–0.90); P < 0.001
Safety
AEs leading to permanent discontinuation of trial product
P < 0.001
Original publication
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. Published 11 November 2023. doi:10.1056/nejmoa2307563
Summarised from the published abstract; every number is checked against it